Free Trial

Sangamo Therapeutics (SGMO) Stock Forecast & Price Target

Sangamo Therapeutics logo
$1.95 -0.01 (-0.51%)
(As of 11/20/2024 ET)

Sangamo Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
2

Based on 3 Wall Street analysts who have issued ratings for Sangamo Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 3 analysts, 1 has given a hold rating, and 2 have given a buy rating for SGMO.

Consensus Price Target

$7.00
258.97% Upside
According to the 3 analysts' twelve-month price targets for Sangamo Therapeutics, the average price target is $7.00. The highest price target for SGMO is $10.00, while the lowest price target for SGMO is $2.00. The average price target represents a forecasted upside of 258.97% from the current price of $1.95.
Get the Latest News and Ratings for SGMO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Sangamo Therapeutics and its competitors.

Sign Up

SGMO Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$7.00$2.67$2.67$4.68
Forecasted Upside258.97% Upside120.39% Upside210.95% Upside1,204.77% Upside
Consensus Rating
Moderate Buy
Hold
Hold
Hold
This Bull Market Indicator called NVDA at $116 (Ad)

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

SGMO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SGMO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Sangamo Therapeutics Stock vs. The Competition

TypeSangamo TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside258.97% Upside26,931.60% Upside9.83% Upside
News Sentiment Rating
Neutral News

See Recent SGMO News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/14/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00+362.96%
11/14/2024Barclays
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$3.00 ➝ $9.00+278.15%
3/14/2024Royal Bank of Canada
4 of 5 stars
 Reiterated RatingSector Perform ➝ Sector Perform$2.00+145.10%
11/7/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
11/6/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Equal Weight$1.00+110.52%
8/11/2023Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Argyrides
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$16.00 ➝ $10.00+825.92%
4/28/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$4.20 ➝ $3.90+178.57%
4/28/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$5.00 ➝ $1.50-6.25%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 08:44 AM ET.


SGMO Forecast - Frequently Asked Questions

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Sangamo Therapeutics is $7.00, with a high forecast of $10.00 and a low forecast of $2.00.

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There is currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SGMO shares.

According to analysts, Sangamo Therapeutics's stock has a predicted upside of 258.97% based on their 12-month stock forecasts.

Sangamo Therapeutics has been rated by research analysts at Barclays, and HC Wainwright in the past 90 days.

Analysts like Sangamo Therapeutics less than other "medical" companies. The consensus rating score for Sangamo Therapeutics is 2.67 while the average consensus rating score for "medical" companies is 2.80. Learn more on how SGMO compares to other companies.


This page (NASDAQ:SGMO) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners